UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
(Amendment No.          )
Filed by the Registrant ý
Filed by a party other than the Registrant o
Check the appropriate box:
oPreliminary Proxy Statement
oConfidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
oDefinitive Proxy Statement
ý
Definitive Additional Materials
oSoliciting Material under §240.14a-12
________________________________________________________________________________________________________
JOUNCE THERAPEUTICS, INC.
(Name of Registrant as Specified In Its Charter)
________________________________________________________________________________________________________



(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
ýNo Fee required
oFee paid previously with preliminary materials.
oFee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11








jnce_noticex2022x1a.jpg




jnce_noticex2022x2a.jpg

Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Jounce Therapeutics Charts.
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Jounce Therapeutics Charts.